Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KT-333 · 1 trial · 6 indications
Incidence and severity of adverse events as assessed by CTCAE v5.0 Phase 1a/1b
To establish the Maximum Tolerated Dose (MTD) Phase 1a
Number of Participants with protocol specified Dose Limiting Toxicities (DLTs) Phase 1a
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation Lymphomas | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1a Dose Escalation Solid Tumors | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1b Dose Expansion PTCL | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1b Dose Expansion CTCL | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1b Dose Expansion LGL-L | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1b Dose Expansion Solid Tumor | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1a Dose Escalation LGL-L | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Phase 1a Dose Escalation T-PLL | EXPERIMENTAL | KT-333 dosed IV weekly in 28 day cycles |
| Name | Type | Description |
|---|---|---|
| KT-333 | DRUG | KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level. |
Inclusion Criteria: 1. Phase 1a Only: Cytologically or pathologically confirmed Lymphomas (including Hodgkin's, B-cell, T-cell, Small Lymphocytic, or Natural-Killer (NK)-cell Lymphomas and LGL-L), T-PLL and solid tumors with the exception of chronic lymphocytic leukemia (CLL) Note: Patients with in...
KT-333 is an investigational small molecule being studied for the treatment of Non Hodgkin Lymphoma (NHL). It is also being evaluated in other blood cancers and solid tumors, including Peripheral T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Large Granular Lymphocytic Leukemia, T-cell Prolymphocytic Leukemia, and solid tumors.
KT-333 is being developed by Kymera Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KYMR. The company is conducting clinical research on this investigational small molecule for oncology indications.
KT-333 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received Fast Track and Orphan Drug designations from the FDA for its studied indications.
KT-333 has one completed Phase 1 clinical trial, registered as NCT05225584. This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of KT-333 in adult patients with refractory lymphoma, large granular lymphocytic leukemia, and solid tumors. The trial enrolled 56 participants in the United States.
KT-333 is a small molecule developed by Kymera Therapeutics. The specific molecular target of KT-333 has not been disclosed in the available clinical trial information. The drug is being studied for its potential activity in hematologic malignancies and solid tumors.